These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 24329800)

  • 1. Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.
    Ghosh A; Holland AM; van den Brink MR
    Immunol Rev; 2014 Jan; 257(1):226-36. PubMed ID: 24329800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.
    Cieri N; Mastaglio S; Oliveira G; Casucci M; Bondanza A; Bonini C
    Immunol Rev; 2014 Jan; 257(1):165-80. PubMed ID: 24329796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.
    Ghosh A; Dogan Y; Moroz M; Holland AM; Yim NL; Rao UK; Young LF; Tannenbaum D; Masih D; Velardi E; Tsai JJ; Jenq RR; Penack O; Hanash AM; Smith OM; Piersanti K; Lezcano C; Murphy GF; Liu C; Palomba ML; Sauer MG; Sadelain M; Ponomarev V; van den Brink MR
    J Clin Invest; 2013 Jun; 123(6):2654-62. PubMed ID: 23676461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytolytic pathways in haematopoietic stem-cell transplantation.
    van den Brink MR; Burakoff SJ
    Nat Rev Immunol; 2002 Apr; 2(4):273-81. PubMed ID: 12001998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
    Zilberberg J; Feinman R; Korngold R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
    Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J
    Blood; 2004 Aug; 104(4):1210-6. PubMed ID: 15090450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunobiology of allogeneic hematopoietic stem cell transplantation.
    Welniak LA; Blazar BR; Murphy WJ
    Annu Rev Immunol; 2007; 25():139-70. PubMed ID: 17129175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.
    Sangiolo D; Mesiano G; Carnevale-Schianca F; Piacibello W; Aglietta M; Cignetti A
    Expert Opin Biol Ther; 2009 Jul; 9(7):831-40. PubMed ID: 19463075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.
    Wang H; Yang YG
    Immunol Rev; 2014 Mar; 258(1):30-44. PubMed ID: 24517424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
    Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
    Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
    Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
    PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.
    Warren EH; Deeg HJ
    Tissue Antigens; 2013 Apr; 81(4):183-93. PubMed ID: 23510414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
    Du W; Cao X
    Front Immunol; 2018; 9():2979. PubMed ID: 30631325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking.
    Hu R; Liu Y; Song Y; Su M; Lu X; Rood D; Lai L
    Br J Haematol; 2016 Nov; 175(3):505-516. PubMed ID: 27447780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cells require TRAIL for optimal graft-versus-tumor activity.
    Schmaltz C; Alpdogan O; Kappel BJ; Muriglan SJ; Rotolo JA; Ongchin J; Willis LM; Greenberg AS; Eng JM; Crawford JM; Murphy GF; Yagita H; Walczak H; Peschon JJ; van den Brink MR
    Nat Med; 2002 Dec; 8(12):1433-7. PubMed ID: 12426560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-Versus-Solid-Tumor Effect: From Hematopoietic Stem Cell Transplantation to Adoptive Cell Therapies.
    Barisic S; Childs RW
    Stem Cells; 2022 Jun; 40(6):556-563. PubMed ID: 35325242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.
    Verneris MR; Ito M; Baker J; Arshi A; Negrin RS; Shizuru JA
    Biol Blood Marrow Transplant; 2001; 7(10):532-42. PubMed ID: 11760085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
    Zakrzewski JL; Suh D; Markley JC; Smith OM; King C; Goldberg GL; Jenq R; Holland AM; Grubin J; Cabrera-Perez J; Brentjens RJ; Lu SX; Rizzuto G; Sant'Angelo DB; Riviere I; Sadelain M; Heller G; Zúñiga-Pflücker JC; Lu C; van den Brink MR
    Nat Biotechnol; 2008 Apr; 26(4):453-61. PubMed ID: 18376399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.
    Hardy NM; Mossoba ME; Steinberg SM; Fellowes V; Yan XY; Hakim FT; Babb RR; Avila D; Gea-Banacloche J; Sportès C; Levine BL; June CH; Khuu HM; Carpenter AE; Krumlauf MC; Dwyer AJ; Gress RE; Fowler DH; Bishop MR
    Clin Cancer Res; 2011 Nov; 17(21):6878-87. PubMed ID: 21948234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.